BioArctic Valuation
Is BIOA B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BIOA B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIOA B (SEK234.2) is trading below our estimate of fair value (SEK730.1)
Significantly Below Fair Value: BIOA B is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIOA B?
Other financial metrics that can be useful for relative valuation.
| What is BIOA B's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 20.69b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 80.1x |
| Enterprise Value/EBITDA | -202.2x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does BIOA B's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.9x | ||
BONEX Bonesupport Holding | 29.7x | 20.7% | SEK 17.8b |
VITR Vitrolife | 1.7x | 105.7% | SEK 23.4b |
BIOG B BioGaia | 5.7x | 10.2% | SEK 12.6b |
SOBI Swedish Orphan Biovitrum | 2.6x | 25.0% | SEK 97.1b |
BIOA B BioArctic | 20.8x | 50.9% | SEK 20.8b |
Price-To-Book vs Peers: BIOA B is expensive based on its Price-To-Book Ratio (20.8x) compared to the peer average (9.9x).
Price to Earnings Ratio vs Industry
How does BIOA B's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: BIOA B is expensive based on its Price-To-Book Ratio (20.8x) compared to the Swedish Biotechs industry average (2.2x).
Price to Book Ratio vs Fair Ratio
What is BIOA B's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 20.8x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate BIOA B's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 224.80 | SEK 368.00 +63.7% | 11.8% | SEK 450.00 | SEK 325.00 | n/a | 5 |
| Jun ’25 | SEK 242.60 | SEK 368.00 +51.7% | 11.8% | SEK 450.00 | SEK 325.00 | n/a | 5 |
| May ’25 | SEK 195.00 | SEK 366.20 +87.8% | 12.2% | SEK 450.00 | SEK 325.00 | n/a | 5 |
| Apr ’25 | SEK 215.40 | SEK 366.20 +70.0% | 12.2% | SEK 450.00 | SEK 325.00 | n/a | 5 |
| Mar ’25 | SEK 219.20 | SEK 365.20 +66.6% | 12.2% | SEK 450.00 | SEK 325.00 | n/a | 5 |
| Feb ’25 | SEK 218.00 | SEK 376.40 +72.7% | 8.8% | SEK 440.00 | SEK 342.00 | n/a | 5 |
| Jan ’25 | SEK 267.80 | SEK 369.33 +37.9% | 11.1% | SEK 450.00 | SEK 312.00 | n/a | 6 |
| Dec ’24 | SEK 231.80 | SEK 372.40 +60.7% | 11.9% | SEK 450.00 | SEK 312.00 | n/a | 5 |
| Nov ’24 | SEK 221.20 | SEK 392.00 +77.2% | 8.8% | SEK 450.00 | SEK 356.00 | n/a | 5 |
| Oct ’24 | SEK 283.00 | SEK 392.00 +38.5% | 8.8% | SEK 450.00 | SEK 356.00 | n/a | 5 |
| Sep ’24 | SEK 314.40 | SEK 392.00 +24.7% | 8.8% | SEK 450.00 | SEK 356.00 | n/a | 5 |
| Aug ’24 | SEK 298.80 | SEK 392.00 +31.2% | 8.8% | SEK 450.00 | SEK 356.00 | n/a | 5 |
| Jul ’24 | SEK 282.00 | SEK 395.20 +40.1% | 10.6% | SEK 460.00 | SEK 356.00 | SEK 235.40 | 5 |
| Jun ’24 | SEK 326.20 | SEK 395.20 +21.2% | 10.6% | SEK 460.00 | SEK 356.00 | SEK 242.60 | 5 |
| May ’24 | SEK 264.40 | SEK 395.20 +49.5% | 10.6% | SEK 460.00 | SEK 356.00 | SEK 195.00 | 5 |
| Apr ’24 | SEK 251.40 | SEK 399.20 +58.8% | 9.9% | SEK 460.00 | SEK 356.00 | SEK 215.40 | 5 |
| Mar ’24 | SEK 298.20 | SEK 399.20 +33.9% | 9.9% | SEK 460.00 | SEK 356.00 | SEK 219.20 | 5 |
| Feb ’24 | SEK 311.40 | SEK 367.80 +18.1% | 22.5% | SEK 460.00 | SEK 220.00 | SEK 218.00 | 5 |
| Jan ’24 | SEK 272.00 | SEK 356.20 +31.0% | 23.3% | SEK 460.00 | SEK 220.00 | SEK 267.80 | 5 |
| Dec ’23 | SEK 292.20 | SEK 356.20 +21.9% | 23.3% | SEK 460.00 | SEK 220.00 | SEK 231.80 | 5 |
| Nov ’23 | SEK 232.60 | SEK 356.25 +53.2% | 26.0% | SEK 460.00 | SEK 220.00 | SEK 221.20 | 4 |
| Oct ’23 | SEK 271.60 | SEK 281.25 +3.6% | 36.7% | SEK 460.00 | SEK 220.00 | SEK 283.00 | 4 |
| Sep ’23 | SEK 92.80 | SEK 266.33 +187.0% | 23.3% | SEK 354.00 | SEK 220.00 | SEK 314.40 | 3 |
| Aug ’23 | SEK 105.60 | SEK 266.33 +152.2% | 23.3% | SEK 354.00 | SEK 220.00 | SEK 298.80 | 3 |
| Jul ’23 | SEK 78.50 | SEK 225.00 +186.6% | 1.8% | SEK 230.00 | SEK 220.00 | SEK 282.00 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.